Abstract 6226: Single-cell analysis reveals clonally expanded CD57+ CD8 T cells in periphery are associated with response to PD-L1 blockade in bladder cancer patients

Mahesh Yadav(University of Florida), Sanjeev Mariathasan(Kaiser Permanente San Francisco Medical Center), Leesun Kim(Ulsan National Institute of Science and Technology), Alessandra Nardin(Singapore Immunology Network), Shomyesh Sanjabi, Ana Milojkovic(Seascape Consultants (United Kingdom)), Kobe Yuen(La Roche College), Evan W. Newell(Agency for Science, Technology and Research), Andrew J. Wallace(St Mary's Hospital), Xiangnan Guan(Unknown), Deepali Rishipathak, Siming Ma, Michael Fehlings(University of Toronto), Alireza Tafazzol
Cancer Research
June 15, 2022
10.1158/1538-7445.am2022-6226
Cited by 0

Related Papers

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
|The Lancet|2016|3.7k
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
|The Lancet|2016|2.2k
Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial
|The Lancet|2017|1.4k
Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial
|The Lancet|2020|786
ctDNA guiding adjuvant immunotherapy in urothelial carcinoma
|Nature|2021|603